influencing the production of a molecule that is a major target in several approved immune "checkpoint inhibitor" therapies, such as pembrolizumab (Keytruda). Dr. Watson and his research team are currently collaborating with several oncologists, dermatology pathologists, and surgeons at McGill Universit

yst: MRK's Januvia franchise will likely feel pressure from the positive EMPA-REG OUTCOME data but we expect MRK to get a boost from FDA approval of Keytruda in 2nd line NSCLC soon (FDA action date Oct 2) and its HCV doublet grazoprevir/elbasvir by early next year (FDA action date Jan 28). TheStreet Rati

y doubled in the past decade, from an average of $5000 per month to more than $10,000 per month. The price for cancer drugs like Yervoy, Opdivo and Keytruda routinely exceeds $120,000 a year. Some other specialty drugs have even higher prices. Cerezyme for Gaucher disease costs about $300,000 per year fo

J.P.Morgan MRK/BMY Restricted Keytruda Label as Expected; See Opdivo Maintaining Leadership Position - ALERT Today, the FDA approved Keytruda (PD-1) with a companion diagnostic (PD-L1 IHC 22C3 pharmDx test) for second-line PD-L1+ lung cancer patients. The restricted label is generally in

allowing patients to beat this killer and enabling them to live productive lives for decades. Last w=ek I did a piece on the new immunotherapy drug Keytruda (pembrolizumab) which the U.S. Food and Drug Administration approved several weeks ago to t=eat patients who had advanced melanoma that had spread t

finally caught up to him: "I have run out of standard treatments. Chemo is getting less effective =ith increasing side effects. There is a new drug Keytruda it has been =pproved for some cancers but is still experimental for prostate cancer. =ttps://prostatecancernewstoday.com/pembrolizumab-immune-therap